ENS-002 leverages a carefully selected trio of microbes to subdue virulent, inflammation-causing S. aureus, a core microbial driver of atopic dermatitis, offering a potential novel avenue for ...

As Delhi’s AQI hits a new high, it is essential to know the effect it can have on our skin. Know the preventive measures from ...

Aclaris Therapeutics has secured an exclusive license from Biosion for the global rights to two new antibodies.

MJH Life Sciences®, a premier provider of health care events, media, and education, today announced the acquisition of the Revolutionizing Atopic Dermatitis (RAD) Annual Meeting, a preeminent ...

Stay informed with Hindustan Times' live updates! Track the latest lifestyle news including fashion trends, style guide & ...

Andrew Rosenberg, DVM, DACVD, provided an overview of Janus kinase inhibitors for treating canine atopic dermatitis ...

Aclaris Therapeutics has entered an exclusive licensing deal with Biosion for two antibodies, BSI-045B for atopic dermatitis ...

Dupilumab (Dupixent), a fully human monoclonal antibody that targets the interleukin (IL)-4 and IL-13 pathways, is currently ...

Eli Lilly’s Ebglyss (lebrikizumab-lbkz) showed improvement in skin clearance and itch relief for most patients with ...

Enhances Aclaris’ pipeline with complementary biologics portfolio -- Expands leadership team with addition of seasoned ...

Apogee Therapeutics' APG777 shows promise in treating atopic dermatitis with less frequent dosing. See why I rate APGE stock ...

Eczema is relatively common, affecting 20 percent of children and 10 percent of adults around the world (1). If you are one of the many who experiences eczema, you know the symptoms, which can include ...